Recruiting
Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure - CV019-010
Updated: 8 February, 2021 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Participants currently hospitalized for acute decompensated heart failure (ADHF) - Participants must be hemodynamically stable, as assessed by the investigator - Men must agree to follow specific methods of contraception, if applicable, while participating in the trial - Women participants must have documented proof that they are not of childbearing potential Exclusion Criteria: - Acute cardiovascular condition other than heart failure (HF) decompensation - Cardiogenic shock at presentation to emergency room (ER) or at any time before randomization - Recipient of ventricular assist devices or use of any cardiac extracorporeal devices, within 12 weeks of study randomization - Participants with contraindications to vasodilator therapy such as restrictive or obstructive cardiomyopathy, severe mitral or aortic stenosis Other protocol-defined inclusion/exclusion criteria apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information